Minerva Surgical (Minerva Surgical) ROCE % : -42.61% (As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Minerva Surgical ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Minerva Surgical's annualized ROCE % for the quarter that ended in Sep. 2023 was -42.61%.

Minerva Surgical ROCE % Historical Data

The historical data trend for Minerva Surgical's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Minerva Surgical ROCE % Chart

Minerva Surgical Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

ROCE %

-109.55

-13.86

-12.88

-42.04

Minerva Surgical Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
ROCE %	Get a 7-Day Free Trial										-63.99	-36.09	-66.85	-46.39	-42.61

Minerva Surgical ROCE % Calculation

Minerva Surgical's annualized ROCE % for the fiscal year that ended in Dec. 2022 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	-30.879	/	( ( (115.092 - 22.809)	+	(68.9 - 14.278) )	/ 2 )
	=	-30.879	/	( (92.283	+	54.622)	/ 2 )
	=	-30.879	/	73.4525
	=	-42.04 %

Minerva Surgical's ROCE % of for the quarter that ended in Sep. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2023 )		(Q: Jun. 2023 )		(Q: Sep. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2023 )		(Q: Jun. 2023 )		(Q: Sep. 2023 )
	=	-24.024	/	( ( (79.303 - 18.078)	+	(72.785 - 21.251) )	/ 2 )
	=	-24.024	/	( ( 61.225	+	51.534 )	/ 2 )
	=	-24.024	/	56.3795
	=	-42.61 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2023) EBIT data.

Minerva Surgical (OTCPK:UTRS) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Minerva Surgical ROCE % Related Terms

Thank you for viewing the detailed overview of Minerva Surgical's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Minerva Surgical (Minerva Surgical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Minerva Surgical Inc (OTCPK:UTRS) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

4255 Burton Drive, Santa Clara, CA, USA, 95054

Website

https://www.minervasurgical.com

Minerva Surgical Inc is a medical device company that develops therapeutic devices that treat abnormal uterine bleeding in a minimally invasive manner. The Company operates and manages its business as one reportable and operating segment, which is the business of research, development, and sale of therapeutic devices for abnormal uterine bleeding treatment.

Executives

Daniel Cohen	director	C/O ACCELMED, 848 BRICKELL AVE, #901, MIAMI FL 33131
Accelmed Partners Ii L.p.	10 percent owner	2875 NE 191ST, SUITE 500, AVENTURA FL 33180
New Enterprise Associates 13 Lp	10 percent owner	1119 ST PAUL STREET, BALTIMORE MD 21202
Uri Geiger	director, 10 percent owner	221 LATHROP WAY, SUITE I, SACRAMENTO CA 95815
Todd Usen	director, officer: Chief Executive Officer	C/O MINERVA SURGICAL, INC., 4255 BURTON DRIVE, SANTA CLARA CA 95054
Derrick Sung	director	C/O IRHYTHM TECHNOLOGIES, INC., 650 TOWNSEND STREET, SUITE 380, SAN FRANCISCO CA 94103
David M Clapper	director, officer: President and CEO	3003 TASMAN DRIVE, SANTA CLARA CA 95054
Novo Holdings A/s	10 percent owner	TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Jaffe Ross A Md	director	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Evgueni V. Skalnyi	officer: VP Medical Affairs	C/O MINERVA SURGICAL, INC., 4225 BURTON DRIVE, SANTA CLARA CA 95054
Dominique J. Filloux	officer: COO	C/O MINERVA SURGICAL, INC., 4225 BURTON DRIVE, SANTA CLARA CA 95054
Joel R Jung	officer: CFO	1401 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Niquette L. Hunt	director	SOLITON, INC., 5304 ASHBROOK DRIVE, HOUSTON TX 77081
Jill Anderson	director	1600 WEST MERIT PARKWAY, SOUTH JORDAN UT 84095
Nea Partners 13, Limited Partnership	10 percent owner	1119 ST. PAUL STREET, BALTIMORE MD 21202